{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T12:44:43Z","timestamp":1791549883782,"version":"4.3.4"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,3,11]],"date-time":"2015-03-11T00:00:00Z","timestamp":1426032000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2015,3,11]],"date-time":"2015-03-11T00:00:00Z","timestamp":1426032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/ncomms7536","type":"journal-article","created":{"date-parts":[[2015,3,11]],"date-time":"2015-03-11T12:03:14Z","timestamp":1426075394000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":141,"title":["Immunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signalling and protein synthesis"],"prefix":"10.1038","volume":"6","author":[{"given":"Wei","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhewei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Fan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingqian","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimiter S.","family":"Dimitrov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,3,11]]},"reference":[{"key":"BFncomms7536_CR1","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1053\/j.gastro.2004.09.011","volume":"127","author":"FX Bosch","year":"2004","unstructured":"Bosch, F. X., Ribes, J., Diaz, M. & Cleries, R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 127, S5\u2013S16 (2004) .","journal-title":"Gastroenterology"},{"key":"BFncomms7536_CR2","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/S0140-6736(11)61347-0","volume":"379","author":"A Forner","year":"2012","unstructured":"Forner, A., Llovet, J. M. & Bruix, J. Hepatocellular carcinoma. Lancet 379, 1245\u20131255 (2012) .","journal-title":"Lancet"},{"key":"BFncomms7536_CR3","first-page":"1379","volume":"32","author":"H Cao","year":"2012","unstructured":"Cao, H., Phan, H. & Yang, L. X. Improved chemotherapy for hepatocellular carcinoma. Anticancer Res. 32, 1379\u20131386 (2012) .","journal-title":"Anticancer Res."},{"key":"BFncomms7536_CR4","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/j.1872-034X.2012.01113.x","volume":"43","author":"A Gauthier","year":"2013","unstructured":"Gauthier, A. & Ho, M. Role of sorafenib in the treatment of advanced hepatocellular carcinoma: an update. Hepatol. Res. 43, 147\u2013154 (2013) .","journal-title":"Hepatol. Res."},{"key":"BFncomms7536_CR5","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1124\/jpet.110.175786","volume":"337","author":"KF Chen","year":"2010","unstructured":"Chen, K. F. et al. Activation of phosphatidylinositol 3-kinase\/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells. J. Pharmacol. Exp. Ther. 337, 155\u2013161 (2010) .","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BFncomms7536_CR6","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1042\/bj3110561","volume":"311","author":"J Filmus","year":"1995","unstructured":"Filmus, J., Shi, W., Wong, Z. M. & Wong, M. J. Identification of a new membrane-bound heparan sulphate proteoglycan. Biochem. J. 311, 561\u2013565 (1995) .","journal-title":"Biochem. J."},{"key":"BFncomms7536_CR7","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1083\/jcb.200302152","volume":"163","author":"B De Cat","year":"2003","unstructured":"De Cat, B. et al. Processing by proprotein convertases is required for glypican-3 modulation of cell survival, Wnt signaling, and gastrulation movements. J. Cell Biol. 163, 625\u2013635 (2003) .","journal-title":"J. Cell Biol."},{"key":"BFncomms7536_CR8","doi-asserted-by":"publisher","first-page":"275","DOI":"10.2165\/11595360-000000000-00000","volume":"25","author":"M Ho","year":"2011","unstructured":"Ho, M. Advances in liver cancer antibody therapies a focus on glypican-3 and mesothelin. BioDrugs 25, 275\u2013284 (2011) .","journal-title":"BioDrugs"},{"key":"BFncomms7536_CR9","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.ejca.2010.10.024","volume":"47","author":"M Ho","year":"2011","unstructured":"Ho, M. & Kim, H. Glypican-3: a new target for cancer immunotherapy. Eur. J. Cancer 47, 333\u2013338 (2011) .","journal-title":"Eur. J. Cancer"},{"key":"BFncomms7536_CR10","first-page":"5179","volume":"57","author":"HC Hsu","year":"1997","unstructured":"Hsu, H. C., Cheng, W. & Lai, P. L. Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution. Cancer Res. 57, 5179\u20135184 (1997) .","journal-title":"Cancer Res."},{"key":"BFncomms7536_CR11","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1111\/j.1349-7006.2009.01206.x","volume":"100","author":"H Shirakawa","year":"2009","unstructured":"Shirakawa, H. et al. Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Sci. 100, 1403\u20131407 (2009) .","journal-title":"Cancer Sci."},{"key":"BFncomms7536_CR12","doi-asserted-by":"publisher","first-page":"6245","DOI":"10.1158\/0008-5472.CAN-04-4244","volume":"65","author":"MI Capurro","year":"2005","unstructured":"Capurro, M. I., Xiang, Y. Y., Lobe, C. & Filmus, J. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res. 65, 6245\u20136254 (2005) .","journal-title":"Cancer Res."},{"key":"BFncomms7536_CR13","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/hep.26996","volume":"60","author":"W Gao","year":"2014","unstructured":"Gao, W. et al. Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy. Hepatology 60, 576\u2013587 (2014) .","journal-title":"Hepatology"},{"key":"BFncomms7536_CR14","doi-asserted-by":"publisher","first-page":"E1083","DOI":"10.1073\/pnas.1217868110","volume":"110","author":"M Feng","year":"2013","unstructured":"Feng, M. et al. Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proc. Natl Acad. Sci. USA 110, E1083\u2013E1091 (2013) .","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFncomms7536_CR15","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/ijc.24941","volume":"126","author":"SI Zittermann","year":"2010","unstructured":"Zittermann, S. I., Capurro, M. I., Shi, W. & Filmus, J. Soluble glypican 3 inhibits the growth of hepatocellular carcinoma in vitro and in vivo. Int. J. Cancer 126, 1291\u20131301 (2010) .","journal-title":"Int. J. Cancer"},{"key":"BFncomms7536_CR16","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1002\/ijc.25549","volume":"128","author":"M Feng","year":"2011","unstructured":"Feng, M., Kim, H., Phung, Y. & Ho, M. Recombinant soluble glypican 3 protein inhibits the growth of hepatocellular carcinoma in vitro. Int. J. Cancer 128, 2246\u20132247 (2011) .","journal-title":"Int. J. Cancer"},{"key":"BFncomms7536_CR17","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.bbrc.2008.11.033","volume":"378","author":"K Nakano","year":"2009","unstructured":"Nakano, K. et al. Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells. Biochem. Biophys. Res. Commun. 378, 279\u2013284 (2009) .","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"BFncomms7536_CR18","doi-asserted-by":"publisher","first-page":"9832","DOI":"10.1158\/0008-5472.CAN-08-1973","volume":"68","author":"T Ishiguro","year":"2008","unstructured":"Ishiguro, T. et al. Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer. Cancer Res. 68, 9832\u20139838 (2008) .","journal-title":"Cancer Res."},{"key":"BFncomms7536_CR19","doi-asserted-by":"publisher","first-page":"592","DOI":"10.4161\/mabs.20933","volume":"4","author":"Y Phung","year":"2012","unstructured":"Phung, Y., Gao, W., Man, Y. G., Nagata, S. & Ho, M. High-affinity monoclonal antibodies to cell surface tumor antigen glypican-3 generated through a combination of peptide immunization and flow cytometry screening. mAbs 4, 592\u2013599 (2012) .","journal-title":"mAbs"},{"key":"BFncomms7536_CR20","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nrc1891","volume":"6","author":"I Pastan","year":"2006","unstructured":"Pastan, I., Hassan, R., Fitzgerald, D. J. & Kreitman, R. J. Immunotoxin therapy of cancer. Nat. Rev. Cancer 6, 559\u2013565 (2006) .","journal-title":"Nat. Rev. Cancer"},{"key":"BFncomms7536_CR21","doi-asserted-by":"publisher","first-page":"6398","DOI":"10.1158\/1078-0432.CCR-11-0487","volume":"17","author":"RJ Kreitman","year":"2011","unstructured":"Kreitman, R. J. & Pastan, I. Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin. Cancer Res. 17, 6398\u20136405 (2011) .","journal-title":"Clin. Cancer Res."},{"key":"BFncomms7536_CR22","doi-asserted-by":"publisher","first-page":"6300","DOI":"10.1158\/0008-5472.CAN-08-0461","volume":"68","author":"X Du","year":"2008","unstructured":"Du, X., Beers, R., Fitzgerald, D. J. & Pastan, I. Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity. Cancer Res. 68, 6300\u20136305 (2008) .","journal-title":"Cancer Res."},{"key":"BFncomms7536_CR23","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1074\/jbc.M409783200","volume":"280","author":"M Ho","year":"2005","unstructured":"Ho, M., Kreitman, R. J., Onda, M. & Pastan, I. In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin. J. Biol. Chem. 280, 607\u2013617 (2005) .","journal-title":"J. Biol. Chem."},{"key":"BFncomms7536_CR24","doi-asserted-by":"publisher","first-page":"4967","DOI":"10.1128\/jb.169.11.4967-4971.1987","volume":"169","author":"CM Douglas","year":"1987","unstructured":"Douglas, C. M. & Collier, R. J. Exotoxin A of Pseudomonas aeruginosa: substitution of glutamic acid 553 with aspartic acid drastically reduces toxicity and enzymatic activity. J. Bacteriol. 169, 4967\u20134971 (1987) .","journal-title":"J. Bacteriol."},{"key":"BFncomms7536_CR25","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1242\/jcs.140871","volume":"127","author":"M Capurro","year":"2014","unstructured":"Capurro, M., Martin, T., Shi, W. & Filmus, J. Glypican-3 binds to frizzled and plays a direct role in the stimulation of canonical Wnt signaling. J. Cell. Sci. 127, 1565\u20131575 (2014) .","journal-title":"J. Cell. Sci."},{"key":"BFncomms7536_CR26","first-page":"14","volume":"1","author":"W Gao","year":"2011","unstructured":"Gao, W. & Ho, M. The role of glypican-3 in regulating Wnt in hepatocellular carcinomas. Cancer Rep. 1, 14\u201319 (2011) .","journal-title":"Cancer Rep."},{"key":"BFncomms7536_CR27","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.ccr.2012.01.004","volume":"21","author":"A Chaudhary","year":"2012","unstructured":"Chaudhary, A. et al. TEM8\/ANTXR1 blockade inhibits pathological angiogenesis and potentiates tumoricidal responses against multiple cancer types. Cancer Cell 21, 212\u2013226 (2012) .","journal-title":"Cancer Cell"},{"key":"BFncomms7536_CR28","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1016\/j.ejca.2011.12.028","volume":"48","author":"R Arai","year":"2012","unstructured":"Arai, R. et al. Simultaneous inhibition of Src and Aurora kinases by SU6656 induces therapeutic synergy in human synovial sarcoma growth, invasion and angiogenesis in vivo. Eur. J. Cancer 48, 2417\u20132430 (2012) .","journal-title":"Eur. J. Cancer"},{"key":"BFncomms7536_CR29","doi-asserted-by":"publisher","first-page":"4294","DOI":"10.1158\/0008-5472.CAN-09-0396","volume":"69","author":"W Sun","year":"2009","unstructured":"Sun, W., Kalen, A. L., Smith, B. J., Cullen, J. J. & Oberley, L. W. Enhancing the antitumor activity of adriamycin and ionizing radiation. Cancer Res. 69, 4294\u20134300 (2009) .","journal-title":"Cancer Res."},{"key":"BFncomms7536_CR30","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.jhep.2008.08.010","volume":"49","author":"VJ Jasinghe","year":"2008","unstructured":"Jasinghe, V. J. et al. ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft. J. Hepatol. 49, 985\u2013997 (2008) .","journal-title":"J. Hepatol."},{"key":"BFncomms7536_CR31","first-page":"20","volume":"7","author":"R Hassan","year":"2007","unstructured":"Hassan, R. et al. Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. Cancer Immun. 7, 20 (2007) .","journal-title":"Cancer Immun."},{"key":"BFncomms7536_CR32","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/ijc.2910510120","volume":"51","author":"CF Molthoff","year":"1992","unstructured":"Molthoff, C. F., Pinedo, H. M., Schluper, H. M., Rutgers, D. H. & Boven, E. Comparison of 131I-labelled anti-episialin 139H2 with cisplatin, cyclophosphamide or external-beam radiation for anti-tumor efficacy in human ovarian cancer xenografts. Int. J. Cancer 51, 108\u2013115 (1992) .","journal-title":"Int. J. Cancer"},{"key":"BFncomms7536_CR33","doi-asserted-by":"publisher","first-page":"v93","DOI":"10.1093\/annonc\/mdq222","volume":"21 (Suppl 5)","author":"E Van Cutsem","year":"2010","unstructured":"Van Cutsem, E., Nordlinger, B. & Cervantes, A. Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. Ann. Oncol. 21 (Suppl 5), v93\u2013v97 (2010) .","journal-title":"Ann. Oncol."},{"key":"BFncomms7536_CR34","doi-asserted-by":"publisher","first-page":"4695","DOI":"10.1158\/1078-0432.CCR-06-0346","volume":"12","author":"Y Zhang","year":"2006","unstructured":"Zhang, Y. et al. Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing mice. Clin. Cancer Res. 12, 4695\u20134701 (2006) .","journal-title":"Clin. Cancer Res."},{"key":"BFncomms7536_CR35","doi-asserted-by":"publisher","first-page":"8847","DOI":"10.1073\/pnas.95.15.8847","volume":"95","author":"A de La Coste","year":"1998","unstructured":"de La Coste, A. et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc. Natl Acad. Sci. USA 95, 8847\u20138851 (1998) .","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFncomms7536_CR36","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1038\/sj.onc.1207237","volume":"23","author":"A Wichert","year":"2004","unstructured":"Wichert, A., Stege, A., Midorikawa, Y., Holm, P. S. & Lage, H. Glypican-3 is involved in cellular protection against mitoxantrone in gastric carcinoma cells. Oncogene 23, 945\u2013955 (2004) .","journal-title":"Oncogene"},{"key":"BFncomms7536_CR37","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1146\/annurev.med.58.070605.115320","volume":"58","author":"I Pastan","year":"2007","unstructured":"Pastan, I., Hassan, R., FitzGerald, D. J. & Kreitman, R. J. Immunotoxin treatment of cancer. Annu. Rev. Med. 58, 221\u2013237 (2007) .","journal-title":"Annu. Rev. Med."},{"key":"BFncomms7536_CR38","doi-asserted-by":"publisher","first-page":"11730","DOI":"10.1074\/jbc.M111.327767","volume":"287","author":"WM Konsavage Jr","year":"2012","unstructured":"Konsavage, W. M. Jr, Kyler, S. L., Rennoll, S. A., Jin, G. & Yochum, G. S. Wnt\/beta-catenin signaling regulates Yes-associated protein (YAP) gene expression in colorectal carcinoma cells. J. Biol. Chem. 287, 11730\u201311739 (2012) .","journal-title":"J. Biol. Chem."},{"key":"BFncomms7536_CR39","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.cell.2014.06.013","volume":"158","author":"L Azzolin","year":"2014","unstructured":"Azzolin, L. et al. YAP\/TAZ incorporation in the beta-catenin destruction complex orchestrates the Wnt response. Cell 158, 157\u2013170 (2014) .","journal-title":"Cell"},{"key":"BFncomms7536_CR40","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1002\/1097-0142(20010101)91:1<101::AID-CNCR13>3.0.CO;2-K","volume":"91","author":"EM O'Reilly","year":"2001","unstructured":"O'Reilly, E. M. et al. A phase II study of irinotecan in patients with advanced hepatocellular carcinoma. Cancer 91, 101\u2013105 (2001) .","journal-title":"Cancer"},{"key":"BFncomms7536_CR41","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ejca.2005.09.034","volume":"42","author":"V Boige","year":"2006","unstructured":"Boige, V. et al. Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: a multicenter phase II study with dose adjustment according to baseline serum bilirubin level. Eur. J. Cancer 42, 456\u2013459 (2006) .","journal-title":"Eur. J. Cancer"},{"key":"BFncomms7536_CR42","first-page":"185","volume":"5","author":"C Ang","year":"2012","unstructured":"Ang, C. et al. A nonrandomized, phase ii study of sequential irinotecan and flavopiridol in patients with advanced hepatocellular carcinoma. Gastrointest. Cancer Res. 5, 185\u2013189 (2012) .","journal-title":"Gastrointest. Cancer Res."},{"key":"BFncomms7536_CR43","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.1016\/j.ejca.2012.06.023","volume":"48","author":"J Zsiros","year":"2012","unstructured":"Zsiros, J. et al. Efficacy of irinotecan single drug treatment in children with refractory or recurrent hepatoblastoma-a phase II trial of the childhood liver tumour strategy group (SIOPEL). Eur. J. Cancer 48, 3456\u20133464 (2012) .","journal-title":"Eur. J. Cancer"},{"key":"BFncomms7536_CR44","doi-asserted-by":"publisher","first-page":"e81919","DOI":"10.1371\/journal.pone.0081919","volume":"8","author":"H Kim","year":"2013","unstructured":"Kim, H., Gao, W. & Ho, M. Novel immunocytokine IL12-SS1 (Fv) inhibits mesothelioma tumor growth in nude mice. PLoS ONE 8, e81919 (2013) .","journal-title":"PLoS ONE"},{"key":"BFncomms7536_CR45","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.ejca.2003.11.021","volume":"40","author":"MC Bibby","year":"2004","unstructured":"Bibby, M. C. Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages. Eur. J. Cancer 40, 852\u2013857 (2004) .","journal-title":"Eur. J. Cancer"},{"key":"BFncomms7536_CR46","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1158\/1535-7163.MCT-06-0391","volume":"5","author":"BA Teicher","year":"2006","unstructured":"Teicher, B. A. Tumor models for efficacy determination. Mol. Cancer Ther. 5, 2435\u20132443 (2006) .","journal-title":"Mol. Cancer Ther."},{"key":"BFncomms7536_CR47","doi-asserted-by":"publisher","first-page":"8571","DOI":"10.1073\/pnas.1405153111","volume":"111","author":"R Mazor","year":"2014","unstructured":"Mazor, R. et al. Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes. Proc. Natl Acad. Sci. USA 111, 8571\u20138576 (2014) .","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFncomms7536_CR48","doi-asserted-by":"publisher","first-page":"208ra147","DOI":"10.1126\/scitranslmed.3006941","volume":"5","author":"R Hassan","year":"2013","unstructured":"Hassan, R. et al. Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression. Sci. Transl. Med. 5, 208ra147 (2013) .","journal-title":"Sci. Transl. Med."},{"key":"BFncomms7536_CR49","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/BF02631017","volume":"28A","author":"SC Heffelfinger","year":"1992","unstructured":"Heffelfinger, S. C., Hawkins, H. H., Barrish, J., Taylor, L. & Darlington, G. J. SK HEP-1: a human cell line of endothelial origin. In Vitro Cell. Dev. Biol. 28A, 136\u2013142 (1992) .","journal-title":"In Vitro Cell. Dev. Biol."},{"key":"BFncomms7536_CR50","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.jmb.2008.07.054","volume":"382","author":"W Chen","year":"2008","unstructured":"Chen, W., Zhu, Z., Feng, Y., Xiao, X. & Dimitrov, D. S. Construction of a large phage-displayed human antibody domain library with a scaffold based on a newly identified highly soluble, stable heavy chain variable domain. J. Mol. Biol. 382, 779\u2013789 (2008) .","journal-title":"J. Mol. Biol."},{"key":"BFncomms7536_CR51","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1002\/ijc.25557","volume":"128","author":"M Ho","year":"2011","unstructured":"Ho, M., Feng, M., Fisher, R. J., Rader, C. & Pastan, I. A novel high-affinity human monoclonal antibody to mesothelin. Int. J. Cancer 128, 2020\u20132030 (2011) .","journal-title":"Int. J. Cancer"},{"key":"BFncomms7536_CR52","doi-asserted-by":"crossref","unstructured":"Pastan, I. & Ho, M. Antibody Engineering 127\u2013146Springer (2010) .","DOI":"10.1007\/978-3-642-01147-4_10"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/ncomms7536.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/ncomms7536","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/ncomms7536.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T19:16:50Z","timestamp":1717787810000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncomms7536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,11]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,5,5]]}},"alternative-id":["BFncomms7536"],"URL":"https:\/\/doi.org\/10.1038\/ncomms7536","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,11]]},"assertion":[{"value":"11 December 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6536"}}